tirzepatide eu plus hormone therapy increases weight loss Tirzepatide: First Approval | Drugs

nejm.org Novo Nordisk

Avoid entirely

Tirzepatide , the dual GIP/GLP-1 receptor agonist, has demonstrated mean heart rate increases of approximately 2-4 beats per minute in the SURPASS clinical trial program, as reflected in the Mounjaro and Zepbound prescribing information

If you think Wegovy may be a better alternative for you and you are currently taking Mounjaro, you can find more information on switching from Mounjaro to Wegovy in our article

Liquid formulations can degrade during transit if temperatures are not controlled

Stretch Regularly Stretching is a simple way to keep your muscles loose and prevent cramps